1. How do patient-reported outcome measures affect treatment intensification and patient satisfaction in the management of psoriatic arthritis? A cross sectional study of 503 patients.
- Author
-
Coyle C, Watson L, Whately-Smith C, Brooke M, Kiltz U, Lubrano E, Queiro R, Trigos D, Brandt-Juergens J, Choy E, D'Angelo S, Delle Sedie A, Dernis E, Wirth T, Guis S, Helliwell P, Ho P, Hueber A, Joven B, Koehm M, Morales CM, Packham J, Pinto Tasende JA, Ramírez J, Ruyssen-Witrand A, Scrivo R, Twigg S, Welcker M, Soubrier M, Gossec L, and Coates LC
- Subjects
- Humans, Male, Female, Cross-Sectional Studies, Middle Aged, Adult, Severity of Illness Index, Surveys and Questionnaires, Antirheumatic Agents therapeutic use, Aged, United Kingdom, Arthritis, Psoriatic drug therapy, Arthritis, Psoriatic therapy, Patient Reported Outcome Measures, Patient Satisfaction
- Abstract
Objectives: The AsseSSing Impact in pSoriatic Treatment (ASSIST) study investigated prescribing in routine PsA care and whether the patient-reported outcome-PsA Impact of Disease questionnaire (PsAID-12)-impacted treatment. This study also assessed a range of patient and clinician factors and their relationship to PsAID-12 scoring and treatment modification., Methods: Patients with PsA were selected across the UK and Europe between July 2021 and March 2022. Patients completed the PsAID questionnaire and the results were shared with their physician. Patient characteristics, disease activity, current treatment methods, treatment strategies, medication changes and patient satisfaction scores were recorded., Results: A total of 503 patients were recruited. Some 36.2% had changes made to treatment, and 88.8% of these had treatment escalation. Overall, the mean PsAID-12 score was higher for patients with treatment escalation; increase in PSAID-12 score is associated with increased odds of treatment escalation (odds ratio 1.58; P < 0.0001). However, most clinicians reported that PsAID-12 did not impact their decision to escalate treatment, instead supporting treatment reduction decisions. Physician's assessment of disease activity had the most statistically significant effect on likelihood of treatment escalation (odds ratio 2.68, per 1-point score increase). Escalation was more likely in patients not treated with biologic therapies. Additional factors associated with treatment escalation included: patient characteristics, physician characteristics, disease activity and disease impact., Conclusion: This study highlights multiple factors impacting treatment decision-making for individuals with PsA. PsAID-12 scoring correlates with multiple measures of disease severity and odds of treatment escalation. However, most clinicians reported that the PsAID-12 did not influence treatment escalation decisions. Psoriatic Arthritis Impact of Disease (PsAID) scoring could be used to increase confidence in treatment de-escalation., (© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology.)
- Published
- 2025
- Full Text
- View/download PDF